Financial Survey: Vertex Pharmaceuticals (VRTX) vs. Achillion Pharmaceuticals (ACHN)
Vertex Pharmaceuticals (NASDAQ: VRTX) and Achillion Pharmaceuticals (NASDAQ:ACHN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.
This is a summary of recent recommendations for Vertex Pharmaceuticals and Achillion Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vertex Pharmaceuticals presently has a consensus price target of $175.75, indicating a potential upside of 10.95%. Achillion Pharmaceuticals has a consensus price target of $5.30, indicating a potential upside of 77.26%. Given Achillion Pharmaceuticals’ higher probable upside, analysts plainly believe Achillion Pharmaceuticals is more favorable than Vertex Pharmaceuticals.
Earnings & Valuation
This table compares Vertex Pharmaceuticals and Achillion Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vertex Pharmaceuticals||$1.70 billion||23.53||-$112.05 million||$0.78||203.08|
|Achillion Pharmaceuticals||$15.00 million||27.48||-$61.70 million||($0.49)||-6.10|
Achillion Pharmaceuticals has lower revenue, but higher earnings than Vertex Pharmaceuticals. Achillion Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
93.1% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 76.9% of Achillion Pharmaceuticals shares are held by institutional investors. 1.8% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 7.2% of Achillion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Vertex Pharmaceuticals and Achillion Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Vertex Pharmaceuticals has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Achillion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
Vertex Pharmaceuticals beats Achillion Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company’s marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company’s development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.